RxDoctor Payments Data

Patricia Neuman

Medical · Salt Lake City, UTNPI 1275920597

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,005 and has fallen 59.6% since, to $405 in 2025.

$3,645in general payments, 2019–2025

Across 152 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$604
  • Dexcom, Inc.$581
  • AbbVie$436
  • Corcept Therapeutics$404
  • AstraZeneca$224
  • Amgen$218
  • plus $1K from 19 others

What the payments were for

  • Speaking & faculty fees$1253%
  • Food & beverage$3,52097%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,645 in reported general payments places this provider in the 80th percentile of 263 medical providers in Utah.

See all medical providers in Utah

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$25,510
OzempicSemaglutide16$20,108
MounjaroTirzepatide14$13,157
Repatha SureclickEvolocumab11$6,879
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,450
Celecoxib29$650
Omeprazole33$416
Albuterol Sulfate HfaAlbuterol Sulfate17$404
Pantoprazole Sodium22$365
Levothyroxine Sodium44$334
Losartan Potassium30$261
Rosuvastatin Calcium16$219
Atorvastatin Calcium44$218
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$215
Gabapentin14$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$224$25,51019 claims
Novo NordiskOzempic$80$20,10816 claims
Lilly USA, LLCMounjaro$157$13,15714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 263 medical providers in Utah.

Other medical in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →